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Abstract
Background: Immune checkpoint inhibitors have revolutionized cancer therapy since these drugs target inhibitory
pathways on T cells, which result in durable anti-tumor immune responses and significant overall survival for a subset
of cancer patients. These drugs can also lead to toxicities, which require additional research to identify mechanisms of
toxicities and biomarkers that can help to identify patients who will develop immune-related adverse events.
Case presentation: We describe the first case, to our knowledge, of a patient with metastatic urothelial carcinoma
who developed acute rhabdomyolysis with severe polymyositis after treatment with combination immunotherapy
consisting of ipilimumab plus nivolumab (Trial registration: NCT01928394. Registered: 8/21/2013). We found that this
patient had an elevated pre-existing anti-striated muscle antibody titer, which was likely exacerbated with the
immunotherapy treatment thereby resulting in the presentation of acute rhabdomyolysis and severe polymyositis.
Conclusions: This case suggests that immune-related adverse events may be linked to subclinical autoimmune
conditions which highlights the need for additional studies to identify patients who are at risk for toxicities.
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Background
Advances in our understanding of immune checkpoints
have led to the development of novel approaches for cancer
therapy. Ipilimumab is a monoclonal antibody that directly
inhibits the function of the immune checkpoint cytotoxic
T-lymphocyte antigen 4 and it was shown to improve
survival, which led to approval in treatment of patients with
melanoma [1, 2]. Nivolumab targets the programmed
death-1 checkpoint and was approved as treatment for
patients with metastatic melanoma, non-small cell lung
cancer and renal cell carcinoma [3–5]. Recently, combin-
ation therapy with nivolumab plus ipilimumab was shown
to improve progression free survival, which led to approval
of this combination as treatment for patients with meta-
static melanoma [6].
Although immune checkpoint therapies can lead to
significant clinical benefit, they are also associated with
immune-related adverse events (irAEs). As increasing
numbers of these immunomodulatory treatments are under
investigation, clinicians need to become familiar with
diagnosing and controlling irAEs. More importantly, im-
munologic mechanisms and biomarkers that can help to
identify patients at risk for irAEs with immune checkpoint
therapy are critical to help clinicians select appropriate
patients for treatment. We describe here the first case, to
our knowledge, of a patient with metastatic papillary transi-
tional cell carcinoma after three prior chemotherapy
regimens, in whom acute rhabdomyolysis with severe poly-
myositis developed on a clinical trial of ipilimumab plus
nivolumab. We retrospectively identified an elevated pre-
existing anti-striated muscle antibody titer (anti-SM-titer),
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which provides a potential immunologic mechanism and
biomarker for patients at risk for rhabdomyolysis and
polymyositis with immune checkpoint therapy.
Case presentation
The patient, a 73-year-old Chinese man, with no significant
past medical history, presented with hematuria and was
initially treated with a left nephroureterectomy in May
2009. The pathology report showed a papillary transitional
cell carcinoma in the renal pelvis measuring 2.6 cm with
evidence of lymphovascular invasion. At that time, the
patient did not receive adjuvant chemotherapy and did well
until October 2010.
In October 2010, the patient underwent staging workup
which revealed multiple pulmonary metastases. He re-
ceived 7 cycles of gemcitabine combined with carboplatin.
Initially, he experienced response to treatment. However,
there were residual pulmonary nodules and these were
noted to be stable in repeat restaging study.
In September 2011, the patient sought evaluation at the
University of Texas MD Anderson Cancer Center for fur-
ther care. Due to residual pulmonary nodules, he received 2
courses of dose-dense MVAC (Methotrexate 30 mg/m2,
doxorubicin 30 mg/m2, vinblastine 3 mg/m2, cisplatin
70 mg/m2) without further improvement of the residual
lung nodules. After this, he was followed closely without
further treatment.
In July 2013, he presented with dysuria. He underwent
cystoscopy which confirmed tumor involvement in the
bladder. In August 2013, he underwent a radical cysto-
prostatectomy. Pathology revealed a stage 4a urothelial
carcinoma with invasion into the prostatic stroma, surgical
margins were negative, and none of the lymph nodes were
involved by metastatic disease. He received 3 cycles of
chemotherapy consisting of dose-dense MVAC, which was
completed in November 2013. After this, he was followed
closely without further treatment.
In August 2014, he presented with progressive metastatic
disease including new right external iliac lymphadenopathy
and increase in size of pulmonary nodules. He received 3
cycles of pemetrexed every 3 weeks (500 mg/m2) with no
detectable change in the size of measurable disease.
In November 2014, the patient agreed to participate in a
randomized phase 1/2, open-label study of nivolumab
monotherapy or nivolumab combined with ipilimumab (ap-
proved by the Institutional Review Board). He was randomly
assigned to receive treatment with nivolumab (3 mg/kg)
combined with ipilimumab (1 mg/kg) every 3 weeks. He
received the first treatment on November 14, 2014, which
was well-tolerated with no immediate adverse effects. On
December 4, 2014, he received his second treatment. At that
time, he reported mild throat discomfort and tightness in his
jaw when he swallowed; the etiology of these symptoms was
unclear and not thought to be related to the immunotherapy
agents. The patient denied any skin rash, diarrhea, or ab-
dominal pain. His blood test results were within normal
limits, except for an asymptomatic alanine transaminase
(ALT) level of 157 IU/L and an aspartate transaminase level
(AST) of 703 IU/L, which was a grade 3 adverse event per
the Common Terminology Criteria for Adverse Events,
Version 4 (CTCAE). Since the patient did not have any
clinical symptoms such as abdominal pain or nausea/vomit-
ing associated with elevated liver function test (LFTs), a
plan of close observation without changes in treatment was
instituted as per the guideline of clinical trial protocol.
On December 8, 2014, the patient presented to the emer-
gency department with complaints of significant lower back
pain, profound weakness including inability to ambulate,
and difficulty opening his mouth, eating, and speaking. On
physical examination, the patient was noted to have
bilateral ptosis and extraocular muscle weakness. His vital
signs were stable. Laboratory tests showed creatine kinase
(CK) level of 13,710 U/L (reference range; 55–170, CTCAE
grade 4), AST level of 1346 IU/L (reference range; 15–46,
CTCAE grade 4), ALT level of 378 IU/L (reference
range;7–56, CTCAE grade 3), CK-MB level of 149.1 ng/mL
(reference range; 0.6–6.3), creatinine level of 1.5 mg/dL
(reference range; 0.7–1.3), blood urea nitrogen level of
43 mg/dL, troponin I level of 7.98 ng/mL (reference range;
<0.03), alkaline phosphatase level of 44 U/L (reference
range; 38–126), lactate dehydrogenase level of 3697 IU/L
(reference range; 313–618), and the presence of myoglobi-
nuria. An electrocardiogram was unremarkable. The patient
was admitted to the intensive care unit for further care and
subsequently diagnosed with acute rhabdomyolysis associ-
ated with severe polymyositis, which were suspected to
be immune-related toxicities. He received intravenous
fluids and methylprednisolone (1 mg/kg twice daily).
His muscle strength and laboratory tests improved after
the initiation of steroids (Fig. 1). However, on December 12,
2014, he was noted to have increasing use of accessory mus-
cles to assist in breathing. Due to his worsening respiratory
status, which was also thought to be secondary to muscle
weakness, infliximab was administered as an additional im-
munosuppressive agent and the patient was also intubated.
On December 12, 2014, a paraneoplastic antibody panel
was negative with the exception of elevated anti-SM-titer
(1:61440 [normal ≤ 1:120]). The presence of elevated anti-
SM-titer provided a potential immunologic mechanism for
the patient’s presentation with rhabdomyolysis and poly-
myositis. We had not previously checked an anti-SM-titer
prior to treatment but, we had a pre-treatment blood sample
and used it to retrospectively evaluate the patient’s pre-
treatment anti-SM-titer. We found the patient’s pre-
treatment anti-SM-titer was already elevated at 1:15360. In
retrospect, it appears that this patient had an underlying
autoimmune disorder that was exacerbated by treatment
with nivolumab plus ipilimumab immunotherapy.
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On December 15, 2014, a muscle biopsy of the
patient’s left thigh revealed fragments of connective
tissue and skeletal muscle fibers with a single minute
focus showing a multinucleate giant cell juxtaposed to
a muscle fiber with very mild features of degeneration.
We analyzed the muscle biopsy, which did not show
any immune cell infiltration and this was likely due
to the fact that the patient already received im-
munosuppressive therapies prior to the biopsy
(Fig. 2).
Fig. 1 Summary of the patient’s hospital stay including changes in laboratory results and treatment. Dotted lines indicate grade 3 adverse events
according to the Common Terminology Criteria for Adverse Events, Version 4. AST indicates aspartate transaminase; ALT, alanine transaminase;
CK-MB, creatinine kinase isoenzyme MB; CK, creatinine kinase; ULN, upper limit of normal; AE, adverse event; IPI, ipilimumab; NIVO, nivolumab;
Trach, tracheostomy; IVIG, intravenous immunoglobulin
Fig. 2 Negative CD3 staining of patient’s muscle biopsy, (20X)
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The patient ultimately received 2 doses of intravenous
immunoglobulin, which was completed in December
2014, and 12 rounds of plasmapheresis, which com-
pleted in February 2015. These treatments resulted in
improvement of his antibody titer and other laboratory
tests (Fig. 1). The patient’s muscle strength improved
and tracheostomy was performed in December 2014 to
provide intermittent respiratory support while the pa-
tient was participating in physical therapy rehabilitation.
Unfortunately, on March 2015, imaging studies showed
progressive disease and the patient was referred to hos-
pice care where he died in April 2015.
Discussion
Immune checkpoint therapies have demonstrated high
response rates and prolonged overall survival in cancer
patients; however, these therapies require education to
recognize and treat related toxicities [4, 5, 7–9]. The
most common reported grade 3–4 adverse events in
combination therapy with ipilimumab plus nivolumab
were gastrointestinal, skin and hepatic [10]. Less com-
mon reported immune related adverse events include
limbic encephalitis, Guillain-Barre syndrome, red cell
aplasia, and nephritis.
Polymyositis associated with immune checkpoint
therapies has been reported before. Hunter et al. described
a patient who developed autoimmune inflammatory
myopathy after treatment with ipilimumab [11]. Liao et al.
reported atypical neurological complications of ipilimu-
mab, such as chronic inflammatory demyelinating poly-
neuropathy, transverse myelitis, or concurrent myositis
and myasthenia gravis–type syndrome [12]. Yoshioka et
al. reported a patient who experienced respiratory discom-
fort 7 weeks after nivolumab infusion [13]. In another case
report, authors reported dermatomyositis 2 weeks after
the first dose of ipilimumab therapy [14]. Min et al.
reported a patient who was treated with anti-PD1 and ex-
perienced severe hypothyroidism and rhabdomyolysis
[15]. The cases highlight rhabdomyolysis and polymyositis
as notable adverse event with immune checkpoint
therapy. An underlying immunologic mechanism for these
previous reports of rhabdomyolysis and polymyositis has
not been established. Here, we propose that immune
checkpoint agents may exacerbate underlying auto-
immune conditions consisting of elevated preexisting
anti-SM-titer, which can elicit rhabdomyolysis and
polymyositis.
Conclusions
Here, we describe irAEs that may be linked to subclin-
ical autoimmune conditions with elevated levels of pre-
existing anti-SM-titer, which highlights the need for
additional studies to identify patients who are at risk for
toxicities. Future studies will be needed to determine the
prevalence of elevated anti-SM-titer cancer patients and
to determine whether these patients are at higher risk of
developing rhabdomyolysis and polymyositis with im-
mune checkpoint therapies. We believe that our experi-
ence may be informative for treating physicians since
immune checkpoint therapies are becoming widely used
in oncology.
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